Acura Pharmaceuticals, Inc (ACUR) is a leading drug manufacturers-specialty & generic business based in the US. Acura Pharmaceuticals is listed on the OTCQB and employs 12 staff. All prices are listed in US Dollars.
|52-week range||$0.14 - $0.45|
|50-day moving average||$0.2273|
|200-day moving average||$0.2571|
|Wall St. target price||$6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.002|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Acura Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acura Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acura Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Acura Pharmaceuticals shares trade at around 7x recent earnings.
Acura Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $483,000.
The EBITDA is a measure of a Acura Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.1 million|
|Operating margin TTM||7.61%|
|Gross profit TTM||$1.2 million|
|Return on assets TTM||8.31%|
|Return on equity TTM||0%|
|Market capitalisation||$5.2 million|
TTM: trailing 12 months
There are currently 89,846 Acura Pharmaceuticals shares held short by investors – that's known as Acura Pharmaceuticals's "short interest". This figure is 18.2% up from 76,004 last month.
There are a few different ways that this level of interest in shorting Acura Pharmaceuticals shares can be evaluated.
Acura Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Acura Pharmaceuticals shares currently shorted divided by the average quantity of Acura Pharmaceuticals shares traded daily (recently around 123076.71232877). Acura Pharmaceuticals's SIR currently stands at 0.73. In other words for every 100,000 Acura Pharmaceuticals shares traded daily on the market, roughly 730 shares are currently held short.
However Acura Pharmaceuticals's short interest can also be evaluated against the total number of Acura Pharmaceuticals shares, or, against the total number of tradable Acura Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acura Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Acura Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.012% of the tradable shares (for every 100,000 tradable Acura Pharmaceuticals shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acura Pharmaceuticals.
Find out more about how you can short Acura Pharmaceuticals stock.
We're not expecting Acura Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Acura Pharmaceuticals's shares were split on a 1:5 basis on 28 August 2015. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acura Pharmaceuticals shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Acura Pharmaceuticals shares which in turn could have impacted Acura Pharmaceuticals's share price.
Over the last 12 months, Acura Pharmaceuticals's shares have ranged in value from as little as $0.14 up to $0.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Acura Pharmaceuticals's is 0.8004. This would suggest that Acura Pharmaceuticals's shares are less volatile than average (for this exchange).
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.